Eyeworld

References: 1. Xiidra [package insert]. East Hanover, NJ: Novartis Pharmaceuticals Corporation; November 2019. 2. TFOS DEWS II Research Subcommittee. Report of the Research Subcommittee of the Tear Film & Ocular Surface Society Dry Eye WorkShop II (2017). Ocul Surf. 2017;15(3):269-275. Indication Xiidra ® (lifitegrast ophthalmic solution) 5% is indicated for the treatment of signs and symptoms of dry eye disease (DED). Important Safety Information Xiidra is contraindicated in patients with known hypersensitivity to lifitegrast or to any of the other ingredients. In clinical trials, the most common adverse reactions reported in 5-25% of patients were instillation site irritation, dysgeusia and reduced visual acuity. Other adverse reactions reported in 1% to 5% of the patients were blurred vision, conjunctival hyperemia, eye irritation, headache, increased lacrimation, eye discharge, eye discomfort, eye pruritus and sinusitis. To avoid the potential for eye injury or contamination of the solution, patients should not touch the tip of the single-use container to their eye or to any surface. Contact lenses should be removed prior to the administration of Xiidra and may be reinserted 15 minutes following administration. Safety and efficacy in pediatric patients below the age of 17 years have not been established. For additional safety information, see accompanying Brief Summary of Safety Information on the adjacent page and Full Prescribing Information on Xiidra-ECP.com. Xiidra blocks the interaction of ICAM-1 and LFA-1, which is thought to be a key mediator of the inflammation behind Dry Eye Disease. 1 Check out Xiidra-ECP.com XIIDRA MAY INTERRUPT THE CYCLE OF INFLAMMATION CENTRAL TO DRY EYE DISEASE 1 The exact mechanism of action of Xiidra in Dry Eye Disease is not known. 1 THE CYCLE OF INFLAMMATION 2 Signs & Symptoms Inflammation Ocular Surface Stress Tear Film Instability In vitro studies have shown that Xiidra may inhibit the recruitment of previously activated T cells, the activation of newly recruited T cells, and the release of pro-inflammatory cytokines. 1 Novartis Pharmaceuticals Corporation East Hanover, New Jersey 07936-1080 ©2019 Novartis 11/19 XIA-1383635

• Blank Page
• Blank Page (1)